CEBPA and acute myeloid leukemia: It has been reported that not all CEBPA mutations carry favorable prognosis for AML (42); moreover, concomitant mutation in WT1 (classified as “myeloid.gene.R”) has been reported to predict poor prognosis in AML even when CEBPA biallelic mutations were present (86).